VAERS Explorer
Back to explore

Report #2869073

Received Oct 28, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
82 yrs
State
ND
Recovered
Not recovered
Vaccinated
Oct 17, 2025
Onset
Oct 26, 2025
Days to onset
9
Hospital days
—

Vaccines (2)

TypeNameManufacturerDoseLotRoute / Site
PNC20PNEUMO (PREVNAR20)PFIZER\WYETH5MA2506IM / RA
RSVRSV (MRESVIA)MODERNA13041770IM / LA

Symptoms (3)

Injection site erythemaInjection site pruritusInjection site rash

Symptom narrative

On 10/27/25, the patient contacted the pharmacy to report on 10/26/25 she developed an area of redness that was itching and had developed a rash. The area was approximately 2 inches in diameter to the right upper arm injection site. She denies tenderness to the area. The patient had received a pneumococcal vaccine to the right deltoid on 10/17/25. The patient reports that on 10/27/25 she noted an area that was reddened with increased pain with palpation to the left upper arm injection site. The area was approximately 2 inches in diameter. The patient had received a RSV mResvia vaccination to the right deltoid on 10/17/25. The patient denies shortness of breath or fever. The patient denies swelling to the injection sites. She denies chills, body aches or malaise. The patient denies illness within the last month. The patient reports that she does develop a rash following a cortisone injection. The patient will develop a reddened face with consumption of alcohol. The patient reports that bandaids will "pull off her skin" if she leaves them in place for too long. The patient denies additional allergies. The patient's injection sites had been prepped with an alcohol pad and a latex free bandaid was applied to the injection sites following the injection. The patient reports she removed the bandaids the day of the injection and no irritation to the injection site or surrounding tissue was noted at that time. The patient has alavert allergy tablets available as needed. The patient has topical hydrocortisone that she uses as needed. The patient took alavert on 10/27/25 and 10/28/25. The patient used topical hydrocortisone for the area of itching. On 10/28/25 the patient reports no further itching. The patient reports improvement of redness to the areas of concern on her upper arms bilaterally. The patient reports that the area of tenderness has improved. The patient denies any further symptoms at this time.